Estrogen decreases the expression of claudin-5 in vascular endothelial cells in the murine uterus.
Vascular endothelial (VE)-cadherin and claudin-5 are major components of the adherens and tight junctions of vascular endothelial cells, respectively, and decreases in their expression are associated with increases in endothelial paracellular permeability. In the uterus, estrogen induces endometrial edema. However, the in vivo effect of estrogen on endothelial paracellular permeability is unknown. Therefore, we studied the expression of VE-cadherin and claudin-5 in vascular endothelial cells in murine uteri stimulated by estrogen or progesterone. Ovariectomized mature mice were injected with estradiol-17β (1 μg/mouse) or progesterone (1 mg/mouse) at intervals of 24 hours for 6 days. The frozen transverse sections of the uteri of these mice and untreated mice were stained for CD31 (vascular endothelial cell marker) plus VE-cadherin or claudin-5 using a double-immunofluorescence method. Then, the percentages of VE-cadherin- or claudin-5-positive vessels among CD31-positive vessels were examined in the uterine endometria. VE-cadherin and claudin-5 were expressed in most CD31-positive vessels in the endometria of the untreated mice. Progesterone did not affect the expression of both VE-cadherin and claudin-5 and estradiol-17β also did not affect the VE-cadherin expression, but estradiol-17β significantly decreased the claudin-5 expression. This decreasing effect of estradiol-17β was detected from 24 hours later when the water content per a uterus significantly increased. The present study indicates that estrogen, but not progesterone, decreases the expression of claudin-5 in vascular endothelial cells in the murine uterine endometrium from 24 hours later, suggesting that the decrease in the claudin-5 expression contributes to the endometrial edema late after the estrogen stimulation.
Department of Pathology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Masaki
M
Hata
Koji
K
Yamanegi
Naoko
N
Yamada
Hideki
H
Ohyama
Yoriko
Y
Yukitatsu
Keiji
K
Nakasho
Haruki
H
Okamura
Nobuyuki
N
Terada
D000818:Animals; D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D015820:Cadherins / Q000235:genetics / Q000378:metabolism; D062507:Claudin-5 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D004487:Edema / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D004717:Endometrium / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D007279:Injections, Subcutaneous; D008810:Mice, Inbred C57BL; D010052:Ovariectomy; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000378:metabolism; D011374:Progesterone / Q000008:administration & dosage / Q000494:pharmacology; D011372:Progestins / Q000008:administration & dosage / Q000494:pharmacology; D014591:Uterine Diseases / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D014599:Uterus / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D000099152:Cadherin 5
D015703:Antigens, CD; D015415:Biomarkers; D015820:Cadherins; D062507:Claudin-5; D004958:Estradiol; D004967:Estrogens; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D011374:Progesterone; D011372:Progestins; D000099152:Cadherin 5; C491511:Cldn5 protein, mouse